https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Adaptimmune_Therapeutics_PLC_ADR 2026-05-04T05:21:44Z Istoricul versiunilor pentru această pagină din wiki MediaWiki 1.39.2 https://wiki.tradeville.ro/index.php?title=Adaptimmune_Therapeutics_PLC_ADR&diff=447687&oldid=prev 2024-09-28T23:29:32Z

<p>The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ro"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Versiunea anterioară</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Versiunea de la data 29 septembrie 2024 02:29</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Linia 2:</td> <td colspan="2" class="diff-lineno">Linia 2:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Adaptimmune Therapeutics plc (https://www.adaptimmune.com/) is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Adaptimmune Therapeutics plc (https://www.adaptimmune.com/) is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with <ins style="font-weight: bold; text-decoration: none;">[[</ins>ADP<ins style="font-weight: bold; text-decoration: none;">]]</ins>-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td></tr> <!-- diff cache key tradeville_wiki:diff::1.12:old-404699:rev-447687 --> </table>

127.0.0.1 https://wiki.tradeville.ro/index.php?title=Adaptimmune_Therapeutics_PLC_ADR&diff=404699&oldid=prev 2024-09-18T13:35:09Z

<p>Pagină nouă: Pagina dedicata companiei Adaptimmune Therapeutics PLC ADR listata cu simbolul US.ADAP ==Descriere companie== Adaptimmune Therapeutics plc (https://www.adaptimmune.com/) is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple soli...</p> <p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Adaptimmune Therapeutics PLC ADR listata cu simbolul US.ADAP<br /> <br /> ==Descriere companie==<br /> Adaptimmune Therapeutics plc (https://www.adaptimmune.com/) is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.<br /> <br /> ==Grafic actiuni companie==<br /> &lt;iframe key=&quot;tradeville&quot; path=&quot;graficSimbol/US.ADAP&quot; /&gt;<br /> <br /> ==Ultimele stiri despre Adaptimmune Therapeutics PLC ADR (US.ADAP)==<br /> &lt;dynamicpagelist&gt;<br /> category=US.ADAP<br /> count=10<br /> order=descending<br /> addfirstcategorydate=false<br /> &lt;/dynamicpagelist&gt;<br /> <br /> [[Categorie:US.ADAP]][[Categorie:Stiri despre companii]]</div>

Admin